Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Craniopharyngioma 2COVID-19 2Burkitt Lymphoma 2Arthritis, Rheumatoid 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Stroke 1Sarcoma 1Respiratory Tract Infections 1Recurrence 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

pembrolizumab 12Radiotherapy 9avelumab 8Nivolumab 8cemiplimab 4Radiation 4Ipilimumab 4poly ICLC 3atezolizumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3talimogene laherparepvec 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2aldesleukin 2Interferon-beta 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Cisplatin 2Carboplatin 2Biopsy 2veliparib 1vatalanib 1tremelimumab 1tocilizumab 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Merkel Cell × tocilizumab × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡